Non-opioid Pain Patch Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.59 Billion |
| Market Size (2029) | USD 4.16 Billion |
| CAGR (2024 - 2029) | 3.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Non-opioid Pain Patch Market Analysis
The Non-opioid Pain Patch Market size is estimated at USD 3.59 billion in 2024, and is expected to reach USD 4.16 billion by 2029, at a CAGR of 3% during the forecast period (2024-2029).
Factors such as an increase in the burden of pain-related diseases, a rise in research and development of non-opioid patches, and benefits associated with non-opioid pain patches over conventional medications are expected to drive market growth over the forecast period.
The growing burden of pain-related diseases such as arthritis, cancer, and inflammatory bowel diseases is anticipated to increase demand for non-opioid pain patches, thereby boosting market growth. For instance, according to the CDC data published in May 2024, it is estimated that by 2040, 78 million US adults will have arthritis. Arthritis is associated with chronic pain, leading to increased demand for effective pain management treatment, which is expected to boost market growth.
Additionally, the growing burden of cancer is expected to increase the prevalence of pain in cancer patients. It is likely to spur the demand for non-opioid pain patches over the forecast period. For instance, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, an estimated 279,260 new cases of cancer were expected to occur in Spain by the end of 2023, out of which 42,721 were new cases of colorectal cancer, 31,282 were of lung cancer, and 21,694 were of urinary bladder cancer. Thus, the high burden of cancer is expected to increase demand for non-opioid patches, thereby boosting market growth.
Meanwhile, a few other players are conducting extensive R&D by collaborating with educational institutions to introduce new non-narcotic pain patches. For instance, in May 2022, Hisamitsu America Celebrated Salonpas Day with a Free Patch offer from a doctor-recommended OTC pain relief patch brand. Salonpas was named the number-one doctor-recommended brand of pain relief patches in the United States in 2022. However, the availability of alternative treatments and the low adoption rate of non-opioid pain patches due to unawareness are expected to impede the growth of the non-opioid pain patch market.
Therefore, due to the rise in the prevalence of pain-related diseases, coupled with the strategic activities of key players, the market studied is anticipated to witness significant growth over the forecast period. However, the availability of alternative treatments and low adoption of non-opioid patches for pain due to unawareness are expected to hamper market growth.
Non-opioid Pain Patch Market Trends
Lidocaine Patches Segment is Expected to Show Significant Market Growth Over the Forecast Period
Lidocaine patches are the most commonly available for treating chronic and acute pain. Factors such as the rise in the prevalence of pain and product launches by key market players are expected to boost the segment’s growth.
Furthermore, various clinical studies are being conducted to demonstrate the efficacy of lidocaine patches in postoperative pain management, which is expected to bolster market growth over the forecast period. For instance, as per the article published in September 2022 by PubMed, researchers demonstrated that the 5% lidocaine patch is efficacious in acute postoperative pain after unilateral inguinal hernia repair. Thus, such advantages offered by the lidocaine patches are expected to increase market demand and fuel market growth over the forecast period.
Moreover, increasing product launches by key market players are anticipated to boost the market. For instance, in June 2022, Hisamitsu America, a subsidiary of Hisamitsu Pharmaceutical Co. Inc., and the manufacturers of the Salonpas line of pain relief products established the availability of the Salonpas Pain Relieving FLEX Patch Lidocaine 4% featuring thin, flexible, and highly adhesive patch technology.
Similarly, in August 2022, Scilex Holding Company, a commercial biopharmaceutical company, focused on developing and commercializing non-opioid therapies for acute and chronic pain patients. It received the fast-track designation for its investigational drug and device product candidate, SP-103. Scilex is developing SP-103 as a non-opioid triple-strength, non-aqueous lidocaine topical system for treating acute LBP. If approved, SP-103 could become the first FDA-approved lidocaine topical product for treating acute LBP. In addition, the increasing burden of diseases, along with the safety profile and efficacy associated with lidocaine patches, are expected to drive the growth of the non-opioid pain patch market during the forecast period.
Therefore, due to the high efficacy of lidocaine patches and the key players' strategic activities, the segment is anticipated to witness significant growth over the forecast period.
North America is Expected to Witness Healthy Growth in the Non-opioid Pain Patch Market Over the Forecast Period
North America is expected to witness significant growth due to the rising prevalence of pain-related diseases and product launches by key market players in the region.
Chronic pain is one of the primary factors responsible for the market's growth. According to the study published in the JAMA Network in February 2022, it was estimated that one in every five adults in the United States suffered from chronic pain. One in 14 adults experienced severe chronic pain. In addition, countries in North America are increasingly facing scrutiny on the opioid crisis issue from government authorities, which, in turn, is expected to increase the demand for non-opioid alternatives. Thus, the rising disease burden further pushes the need for effective and quick treatment options, which is expected to propel the market's growth over the forecast period.
Similarly, chronic pain, such as nerve pain, chronic pelvic pain, pain related to endometriosis, carpal tunnel syndrome, pain related to gout, and cancer pain, were studied using a variety of complementary therapies. One of the most common cases in North America is cancer-related pain. Thus, the rise in cancer cases is expected to augment market growth over the forecast period. For instance, according to the American Cancer Society 2024 Cancer Statistics, the number of new cancer cases is estimated to be 2.00 in the United States in 2024, up from 1.93 million in 2023. The high burden of cancer is expected to augment the demand for non-opioid pain patches for reducing cancer pain, thereby boosting market growth over the forecast period.
In addition, product launches by key market players are anticipated to boost market growth during the forecast period. For instance, in January 2023, Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company, launched diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma's Flector (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
In February 2022, NEXGEL Inc., a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, reported the launch of its MEDAGEL Bug Bite Relief Patch. These cooling patches, made in the United States using NEXGEL's soothing hydrogel technology, provide instant relief to irritated skin caused by insect bites.
Thus, due to the high prevalence of pain-related diseases and strategic activities by the key players, the region is anticipated to witness significant growth over the forecast period.
Non-opioid Pain Patch Industry Segmentation
The market is fragmented, with fierce competition between existing players and new entrants. Various market players use different technologies to develop products that facilitate effective and prolonged drug release to increase consumer base and product penetration. Some of the market players are Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), and TEH SENG Pharmaceutical Mfg. Co. Ltd, Teikoku Seiyaku Co. Ltd, Teva Pharmaceuticals, and Veridian Healthcare.
Non-opioid Pain Patch Market Leaders
-
Endo Pharmaceuticals Inc.
-
Hisamitsu Pharmaceutical Co. Inc.
-
Teva Pharmaceuticals Industries Ltd.
-
Veridian Healthcare
-
Sanofi
*Disclaimer: Major Players sorted in no particular order
Non-opioid Pain Patch Market News
- February 2024: Scilex Holding Company announced that ZTlido had hit three major milestones since its launch, highlighting the trust patients and healthcare providers had in the product. Symphony Health prescription data suggests that over a million patients have used ZTlido since its debut. Based on Symphony Health's data from January 2023 to November 2023, ZTlido was the most prescribed non-opioid branded pain medication among US pain specialists. In a 2023 patient survey by Scilex, 89% of respondents rated themselves as "completely" or "mostly" satisfied with ZTlido.
- March 2023: Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products, publicized its territory distribution agreement for ZTlido in the Middle East and North Africa with a USD 105 million minimum purchase commitment over five years. ZTlido is a lidocaine topical system approved for relieving neuropathic pain associated with PHN.
Non-opioid Pain Patch Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Pain-related Disorders
4.2.2 Rising R&D in Pain Management Treatments
4.2.3 Benefits Associated with Non-opioid Pain Patches Over Conventional Medications
4.3 Market Restraints
4.3.1 Availability of Alternative Treatments
4.3.2 Low Adoption Rate of Non-opioid Pain Patch due to Unawareness
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Patch Type
5.1.1 Lidocaine Patches
5.1.2 Diclofenac Patches
5.1.3 Capsaicin Patches
5.1.4 Ketoprofen Patches
5.1.5 Other Patch Types
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other Distribution Channels
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Endo Pharmaceuticals Inc.
6.1.2 Hisamitsu Pharmaceutical Co. Inc.
6.1.3 Sanofi
6.1.4 Sorrento Therapeutics (SCILEX Pharmaceuticals)
6.1.5 TEH SENG Pharmaceutical Mfg Co. Ltd
6.1.6 Teikoku Seiyaku Co. Ltd
6.1.7 Teva Pharmaceuticals Industries Ltd
6.1.8 Averitas Pharma
6.1.9 Sparsha Pharma International Pvt. Ltd
6.1.10 Veridian Healthcare
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Non-opioid Pain Patch Industry Segmentation
As per the scope of the report, non-opioid pain patches are primarily used for pain relief. These patches release their medicine content through the skin surface and block the transmission of pain signals.
The non-opioid pain patch market is segmented by patch type, distribution channel, and geography. By patch type, the market is segmented as lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and other patch types. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
| By Patch Type | |
| Lidocaine Patches | |
| Diclofenac Patches | |
| Capsaicin Patches | |
| Ketoprofen Patches | |
| Other Patch Types |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Other Distribution Channels |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Non-opioid Pain Patch Market Research FAQs
How big is the Non-opioid Pain Patch Market?
The Non-opioid Pain Patch Market size is expected to reach USD 3.59 billion in 2024 and grow at a CAGR of 3% to reach USD 4.16 billion by 2029.
What is the current Non-opioid Pain Patch Market size?
In 2024, the Non-opioid Pain Patch Market size is expected to reach USD 3.59 billion.
Who are the key players in Non-opioid Pain Patch Market?
Endo Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Teva Pharmaceuticals Industries Ltd., Veridian Healthcare and Sanofi are the major companies operating in the Non-opioid Pain Patch Market.
Which is the fastest growing region in Non-opioid Pain Patch Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Non-opioid Pain Patch Market?
In 2024, the North America accounts for the largest market share in Non-opioid Pain Patch Market.
What years does this Non-opioid Pain Patch Market cover, and what was the market size in 2023?
In 2023, the Non-opioid Pain Patch Market size was estimated at USD 3.48 billion. The report covers the Non-opioid Pain Patch Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Non-opioid Pain Patch Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pain Patch Industry Report
Statistics for the 2024 Pain Patch market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pain Patch analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
